Eosinophilic Gastrointestinal Disorders (EGID) with Peripheral Eosinophilia: A Retrospective Review at Mayo Clinic
- 8 June 2011
- journal article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (11) , 3254-3261
Abstract
Hypereosinophilic syndrome (HES) is defined by significant eosinophilia (>1,500 eos/μl), which often leads to end-organ damage/dysfunction. It is unclear if the presence of significant peripheral eosinophilia (>1,500 eos/μl) indicates a more aggressive form of eosinophilic gastrointestinal disorder (EGID). A database query of the Mayo Clinic Rochester electronic records (1995–2008) was performed using several search terms for eosinophilic gastrointestinal disease, and 161 records were reviewed. Patients under 18 years age, those without Mayo-reviewed pathology specimens, those with eosinophilic esophagitis only, and/or those with evidence of secondary etiologies for GI eosinophilia were excluded. A total of 39 were found to have primary EGID. We compared individuals with biopsy-proven primary EGID based on whether they had significant peripheral eosinophilia (≥1,500 eos/μl) (group A) or not (group B). Group A tended to have more atopy (A: 12/15; B: 11/24; p = 0.03) and more extensive segmental involvement of the GI tract (p = 0.001). None with available studies had evidence of cardiac (A: 7/15; B: 6/24) or bone marrow (A: 10/15; B: 6/24) involvement. The two thromboembolic events in group A after diagnosis did not translate to significantly greater risk (HR = infinity, p = 0.13; group A vs. B). Doses of initial (A: 40 mg/day; B: 55 mg/day; p = 0.17) and maintenance prednisone (A; 8.75 mg/day; B: 7.5 mg/day; p > 0.90) were similar. Group A was significantly more likely to need maintenance prednisone (77 vs. 8%, p = 0.001), with a median treatment duration of 52 weeks. Recurrence of symptoms (and peripheral eosinophilia) during prednisone taper was common in both groups. Prednisone-sparing agents (hydroxyurea, imatinib mesylate, interferon (IFN)-α2b, anti-interleukin (IL-5) monoclonal antibody) were more commonly used in group A (73 vs. 8%; p < 0.0001). EGID with peripheral eosinophilia ≥1,500/μl is associated with atopy, greater GI segmental involvement, and uncertain risk of thrombosis. The common use of long-term steroids and variable responsiveness to nonsteroidal agents, particularly in group A, underscores the need for targeted therapies.Keywords
This publication has 24 references indexed in Scilit:
- Practical approach to the patient with hypereosinophiliaJournal of Allergy and Clinical Immunology, 2010
- Refining the definition of hypereosinophilic syndromeJournal of Allergy and Clinical Immunology, 2010
- Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trialGut, 2009
- Immunomodulatory therapy of eosinophil‐associated gastrointestinal diseasesClinical & Experimental Allergy, 2008
- Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingBlood, 2007
- Approaches to the treatment of hypereosinophilic syndromes: A workshop summary reportJournal of Allergy and Clinical Immunology, 2006
- Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch testsAnnals of Allergy, Asthma & Immunology, 2005
- Eosinophilic gastrointestinal disorders (EGID)Journal of Allergy and Clinical Immunology, 2004
- Treatment of hypereosinophilic syndrome with imatinib mesilateThe Lancet, 2002
- THE HYPEREOSINOPHILIC SYNDROMEMedicine, 1975